Compare FNWB & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | STXS |
|---|---|---|
| Founded | 1923 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.6M | 86.4M |
| IPO Year | 2012 | 2004 |
| Metric | FNWB | STXS |
|---|---|---|
| Price | $9.80 | $1.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $14.50 | $3.00 |
| AVG Volume (30 Days) | 28.9K | ★ 705.6K |
| Earning Date | 10-29-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.00 | 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | $176,000.00 | ★ $29,346,617.00 |
| Revenue This Year | N/A | $6.04 |
| Revenue Next Year | $4.50 | $33.01 |
| P/E Ratio | $258.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.44 | $0.80 |
| 52 Week High | $12.52 | $2.89 |
| Indicator | FNWB | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 44.91 | 54.65 |
| Support Level | $9.50 | $0.95 |
| Resistance Level | $10.30 | $1.97 |
| Average True Range (ATR) | 0.31 | 0.09 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 35.42 | 98.33 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It offers various products and services, such as commercial business loans, multi-family real estate loans, auto and consumer loans, transaction accounts, savings and money market accounts, online banking services, etc., focused on the lending, deposit, and money movement needs of individuals, businesses and nonprofit organizations. The Group's operations are mainly focused on serving various communities in Washington State, U.S. Substantially all of its income is derived from a diverse base of commercial, mortgage, and consumer lending activities and investments.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.